Home › Phases › Preclinical

Preclinical (83 companies)

Companies with at least one active program at Preclinical.

Ticker	Company	Therapeutic areas	Preclinical programs	Lead stage	Programs
FDMT	4D Molecular Therapeutics	OphthalmologyRespiratory Rare	2	Phase 3	5
ABSI	Absci	DermatologyGI/Hepatology+1	4	Phase 1	7
ACRS	Aclaris Therapeutics	DermatologyRespiratory	1	Phase 2	7
ACRV	Acrivon Therapeutics	Oncology	1	Phase 2	5
ABOS	Acumen Pharmaceuticals	Neurology	2	Phase 2	4
ADAG	Adagene	Oncology	3	Phase 2	9
ADCT	ADC Therapeutics	Oncology	1	Approved	5
ADMA	Adma Biologics	Infectious Disease	1	Approved	4
AGMB	Agomab Therapeutics	ImmunologyRespiratory Rare	2	Phase 2	4
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	2	Approved	10
AKTS	Aktis Oncology	Oncology	1	Phase 1	9
ALDX	Aldeyra Therapeutics	DermatologyOncology+1 Rare	3	NDA Submitted	8
ATHE	Alterity Therapeutics	Neurology Rare	1	Phase 3	2
AMLX	Amylyx Pharmaceuticals	MetabolicNeurology Rare	1	Phase 3	5
APGE	Apogee Therapeutics	DermatologyGI/Hepatology+1 Rare	2	Phase 2	9
APVO	Aptevo Therapeutics	Oncology	6	Phase 1	8
ARDX	Ardelyx	Renal	1	Approved	4
ARVN	Arvinas	NeurologyOncology Rare	3	Approved	15
ATAI	Atai Beckley	Neurology	2	Phase 3	5
BMEA	Biomea Fusion	Metabolic	1	Phase 2	5
BCTX	BriaCell Therapeutics	Oncology	6	Phase 3	8
CRDL	Cardiol Therapeutics	Cardiovascular Rare	1	Phase 3	4
CLRB	Cellectar Biosciences	Oncology	1	Approved	11
IPSC	Century Therapeutics	ImmunologyMetabolic+1 Rare	5	Phase 1	11
COGT	Cogent Biosciences	HematologyOncology Rare	1	NDA Submitted	6
CBIO	Crescent Biopharma	Oncology	1	Phase 1	10
CUE	Cue Biopharma	Oncology	2	Phase 1	4
CTMX	CytomX Therapeutics	Oncology	1	Phase 1	3
DYN	Dyne Therapeutics	MetabolicNeurology Rare	8	NDA Submitted	10
ELTX	Elicio Therapeutics	Oncology	3	Phase 2	6
ELOX	Eloxx Pharmaceuticals	Renal Rare	1	Phase 2	4
ENTA	Enanta Pharmaceuticals	DermatologyImmunology+1	1	Phase 3	6
ERAS	Erasca	Oncology	1	Phase 1	4
EXEL	Exelixis	CardiovascularOncology	1	Approved	21
EYPT	EyePoint	Ophthalmology	1	Phase 3	3
FBIO	Fortress Biotech	DermatologyHematology+1 Rare	1	Approved	12
GUTS	Fractyl Health	Metabolic	1	Phase 3	3
GANX	Gain Therapeutics	MetabolicNeurology Rare	4	Phase 2	5
IMUX	Immunic	GI/HepatologyNeurology	1	Phase 3	4
IMNM	Immunome	Oncology	2	NDA Submitted	9
INAB	IN8bio	ImmunologyOncology	3	Phase 2	6
JBIO	Jade Biosciences	ImmunologyRenal Rare	3	Phase 2	6
KOD	Kodiak Sciences	Ophthalmology	2	Phase 3	7
KURA	Kura Oncology	MetabolicOncology	2	Approved	9
KYTX	Kyverna Therapeutics	ImmunologyNeurology+1 Rare	1	NDA Submitted	7
LXEO	Lexeo Therapeutics	CardiovascularNeurology Rare	4	Phase 1	8
LGVN	Longeveron	CardiovascularMetabolic+1 Rare	1	Phase 2	4
MAIA	MAIA Biotechnology	Oncology	4	Phase 3	7
MDNAF	Medicenna Therapeutics	Oncology	6	Phase 3	9
INKT	MiNK Therapeutics	ImmunologyOncology+1 Rare	3	Phase 2	7
NKTR	Nektar Therapeutics	DermatologyImmunology+2	4	Phase 2	11
NGEN	NervGen Pharma	Neurology	3	Phase 1	4
NRXP	NRX Pharmaceuticals	Neurology	1	NDA Submitted	5
NRIX	Nurix Therapeutics	ImmunologyNeurology+1	1	Phase 2	15
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	3	Phase 3	13
OCS	Oculis Holding	NeurologyOphthalmology	1	Phase 3	5
OMER	Omeros	HematologyNeurology+2 Rare	2	NDA Submitted	7
IRD	Opus Genetics	Ophthalmology Rare	5	Approved	12
ORKA	Oruka Therapeutics	DermatologyImmunology Rare	1	Phase 2	6
KTTA	Pasithea Therapeutics	NeurologyOncology Rare	2	Phase 1	4
PHIO	Phio Pharmaceuticals	Oncology	1	Phase 1	4
PCSA	Processa Pharmaceuticals	GI/HepatologyOncology+1 Rare	1	Phase 2	7
PMN	ProMIS Neurosciences	Neurology Rare	5	Phase 1	6
QNRX	Quoin Pharmaceuticals	DermatologyImmunology Rare	6	Phase 2	8
RVPH	Reviva Pharmaceuticals	CardiovascularDermatology+2 Rare	4	Phase 3	10
SANA	Sana Biotechnology	MetabolicOncology	4	Phase 1	5
SCYX	Scynexis	Infectious Disease	1	Approved	4
SLS	SELLAS Life Sciences Group	Oncology	2	Phase 3	8
SLDB	Solid Biosciences	CardiovascularNeurology Rare	3	Phase 3	6
SPRB	Spruce Biosciences	Metabolic Rare	1	Preclinical	2
GPCR	Structure Therapeutics	MetabolicRespiratory Rare	1	Phase 2	5
STRO	Sutro Biopharma	Oncology	3	Phase 1	4
TNGX	Tango Therapeutics	Oncology	1	Phase 1	6
TSHA	Taysha Gene Therapies	Neurology Rare	2	Phase 3	4
TVTX	Travere Therapeutics	MetabolicRenal Rare	2	Approved	7
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	2	Approved	26
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	2	Approved	8
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	6	Phase 1	7
VTVT	vTv Therapeutics	MetabolicRespiratory Rare	1	Phase 3	8
WVE	Wave Life Sciences	MetabolicNeurology+1 Rare	1	Phase 2	5
XNCR	Xencor	HematologyImmunology+4 Rare	2	Approved	30
ZBIO	Zenas BioPharma	DermatologyImmunology+1 Rare	2	NDA Submitted	11
ZYME	Zymeworks	OncologyRespiratory	4	Approved	11